Pharmacotherapy Of Type 2 Diabetes – The Future


avatar AP Abhay 1 , * , avatar DM Ravichand 1 , avatar V Seshayamma 1 , avatar P Satish chandran 1

Department of Pharmacology, Osmania Medical College, Hyderabad – 500 095, India

how to cite: Abhay A, Ravichand D, Seshayamma V, Satish chandran P. Pharmacotherapy Of Type 2 Diabetes – The Future. Int J Endocrinol Metab. 2006;4(3):e94594. 


In the last decade, explosion in therapeutic op-tions for management of type 2 diabetes mellitus (DM) have increased significantly with advances in recombinant DNA technology, molecular bi-ology, clinical chemistry; analogs of insulin have replaced animal insulin, and may displace NPH, regular lente, ultra lente, insulin’s. Analogs such as insulin glargine, insulin lispro, insulin aspart, and insulin glulisine are becoming mainstream therapy for even type 2 DM Besides oral hypo-glycemic agents i.e., sulphonyl ureas, biguanides and thiazolidinediones, newer insulin analogs and non-insulin antidiabetics are in various stages of development. Incretin analogs, amylin analogs, combined P PAR-γ and α agonists, islet-neogenesis gene-associated protein (INGAP) are most prominent amongst these. This review fo-cuses on pramlintide, an amylin analog, GLP-1 agonists and exenatide, an exendin 4 analog re-cently approved for use in type 2 diabetes by US FDA. Newer insulin delivery methods and drugs have also been reviewed.


This part is available in the PDF file.


  • 1.

    The references are available in the PDF file.